Ignite Creation Date:
2024-05-06 @ 2:02 PM
Last Modification Date:
2024-10-26 @ 1:23 PM
Study NCT ID:
NCT04190667
Status:
UNKNOWN
Last Update Posted:
2019-12-10
First Post:
2019-12-04
Brief Title:
Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer
Sponsor:
Lei Li
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
A Study on the Homologous Recombination Deficiency Status in Chinese Population With Epithelial Ovarian Cancer
Status:
UNKNOWN
Status Verified Date:
2019-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The homologous recombination deficiency HRD status in Chinese population with epithelial ovarian cancer EOC is little known This study would recruit 1300 Chinese EOC patients A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues These 36 genes include BRCA1 BRCA2 ABRAXAS1FAM175A ATM ATR BAP1 BARD1 BRIP1 C11ORF30EMSY CDK12 CHEK1 CHEK2 FANCA FANCC FANCD2 FANCI FANCL MRE11A NBN PALB2 PPP2R2A PTEN RAD50 RAD51B RAD51C RAD51D RAD54B RAD54 MLH1 MSH2 MSH6 PMS2 EPCAM STK11 TP53 CDH1 The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA12 and 150 patients without these mutations to further explore the HRD status The HRD model is based on the loss of heterozygosity LOH telomere allele imbalance TAI and large-scale state transitions LST The mutated genes HRD score model and their relationship with the prognosis would provide a full description of for the Chinese EOC patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None